Synlogic Moves Synthetic Biotics To The Clinic For Rare Metabolic Disease

Synlogic Inc. has evolved into a clinical-stage public company in the span of just four months. The Cambridge, Mass.-based drug developer, pioneering a new class of living medicines that work in the microbiome, has matured considerably since it was spun out of research conducted at the Massachusetts Institute of Technology in late 2013.

In June, Synlogic initiated its first clinical trial testing the lead compound SNYB1020, an oral treatment for hyperammonemia in diseases like urea cycle disorders (UCD) and hepatic encephalopathy (HE). The company is initially focusing on the development of its synthetic biotics for rare genetic metabolic diseases, a focus the company believes represents a straightforward development path. Meanwhile, Synlogic signed a development deal with AbbVie Inc